Takeda pulls out of option deal on MacroGenics' MGD010

13 September 2016

USA-based MacroGenics (Nasdaq: MGNX) has announced that Takeda Pharmaceutical (TYO; 4502) will drop its license and option agreement for MGD010, which has been under development for the treatment of autoimmune diseases.

MacroGenics has regained the worldwide rights to MGD010, a bispecific molecule targeting CD32B and CD79B. The decision by Takeda, Japan’s largest drugmaker, comes earlier than the predefined expiration of its option exercise period and follows Takeda’s recently announced therapeutic area re-prioritization.

Takeda’s decision was not based on the ongoing Phase I study with MGD010. MacroGenics plans to continue to advance the development of this product candidate based on the positive study results reported to date.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK